Engineered FGF2 Variants for Stable Cell Culture Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Wild-type growth factors have high turnover rates, leading to inefficient use and variability in cell culture, high costs, and frequent media replacement, which is wasteful and not suitable for maintaining a constant cell proliferation stimulus.
Innovation Solution
Engineered fibroblast growth factor (FGF) polypeptides with modifications such as amino acid substitutions, deletions, or insertions, enhancing bioactivity, solubility, and stability, particularly thermostability, to replace naturally occurring FGF2 in growth media.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If wild-type growth factors are used in cell culture media, then cell proliferation can be stimulated, but the growth factors degrade rapidly leading to high turnover rates and frequent media replacement
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of FGF2 to create variants with altered stability parameters. Specific substitutions (e.g., Serine to Alanine at position 8, Threonine to Alanine at position 13) change the physical-chemical properties of the protein, increasing its resistance to degradation and extending its functional duration in cell culture media without requiring frequent replacement
2Reliability
If high levels of growth factors are used to maintain stimulus above minimal threshold, then cell proliferation can be maintained, but costs increase and components are wasted
Solution Approach 1:
The engineered FGF2 variants exhibit self-service properties by maintaining their own stability and activity over extended periods. The modified proteins resist degradation autonomously, maintaining effective concentrations throughout the culture period without requiring external intervention or frequent media replacement, thereby reducing component waste while ensuring reliable cell proliferation stimulation
3Reliability
If wild-type FGF2 is used, then natural bioactivity is achieved, but solubility and stability are insufficient for industrial cell culture applications
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions at specific positions within the FGF2 sequence. These localized modifications (e.g., at positions 8, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100) are designed to enhance solubility and stability properties at specific regions of the protein while preserving the critical binding interfaces required for bioactivity
Data Source
AI summary
The invention relates to improved growth factor polypeptide variants, in particular polypeptides comprising a sequence of any one of SEQ ID NOs: 2-7 or a sequence with at least 80% similarity thereto, wherein the FGF polypeptide exhibits increased bioactivity, solubility and/or stability compared to the wild-type FGF2 polypeptide of SEQ ID NO: 1. The invention further provides nucleic acid sequences encoding an FGF polypeptide of the invention and a method of growing an animal cell comprising cultivating the animal cell in a culture medium comprising an FGF polypeptide of the invention is also provided.